tbuckley/cabot-search huggingface dataset:
THYMUS, IMMUNITY, AND ONCOLOGY
Authors: J F FRAUMENI, M D MANNING, C R STARK
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AB0812 Increased Arterial Stiffness is Associated with Compromised Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis: Table 1.
Authors: J. Shen, Q. Shang, E.K. Li, T.Y. Zhu, L. Qin, L.-S. Tam
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Arterial calcification might be an important determinant of arterial stiffness. It has been suggested that vascular calcification might occur in parallel with demineralization of bone, with a reciprocal relationship between arterial stiffening and osteoporosis explaining the epidemiological association of osteoporosis with cardiovascular events. Patients with psoriatic arthritis (PsA) have increased risk of osteoporosis and arterial stiffness. Whether there is any association between volumetric BMD (vBMD)/microstructure and arterial stiffness has never been explored in PsA patients. <h3>Objectives</h3> The aim of this study is to examine the association between vBMD/microstructural features and arterial stiffness in PsA patients. <h3>Methods</h3> 85 PsA patients (43 males; age: 54±12 years) were included. Arterial stiffness was determined by branchial-ankle pulse wave velocity (PWV). vBMD and microstructural features of the distal radius were measured using high-resolution peripheral quantitative computed tomography (HR-pQCT). <h3>Results</h3> No patients had overt cardiovascular diseases (CVD). Patients were divided into 2 groups based on whether their PWV value is &lt; (Low PWV, N=40) or ≥1450 cm/s (High PWV, N=45). Patients in High PWV group were older (60±10 vs 49±10 years, <i>p</i>&lt;0.001), and had more active disease [damaged joint count: 4 (1-9) vs 1 (0-4), <i>p</i>=0.002; ESR: 28 (13-44) vs 11 (6-21) mm/1st hr, <i>p</i>&lt;0.001; CRP: 0.4 (0.2-0.8) vs 0.2 (0.1-0.5) mg/dl, <i>p</i>=0.018]. They also had more hypertension (76% vs 40%, <i>p</i>=0.001), diabetes (36% vs 13%, <i>p</i>=0.014), and overall higher CV risk according to the Framingham risk score (FRS) (FRS 10-year CVD risk &gt;10% in 69% vs 25%, <i>p</i>&lt;0.001), although the body mass index (BMI) was lower (24±4 vs 26±4 kg/m<sup>2</sup>, <i>p</i>=0.041). Total, cortical (ct.) and trabecular (tb.) vBMD were 15.0% (<i>p</i>=0.002), 4.9% (<i>p</i>&lt;0.001) and 18.3% (<i>p</i>=0.002) less in the High PWV group (Table 1); bone microstructure were also inferior as tb. bone volume fraction and thickness were 18.3% (<i>p</i>=0.002), 14.7% (<i>p</i>=0.001) lower; while ct. porosity was 65.6% (<i>p</i>=0.002) higher. The differences in tb. vBMD, bone volume fraction and thickness remained significant after adjustment for age, gender and CVD/osteoporosis risk factors. Patients in High PWV group also had significantly lower biomechanical indices including stiffness, failure load and tb. average stress after adjustment. <h3>Conclusions</h3> PsA patients with increased arterial stiffness have lower vBMD, compromised bone microstructure and strength in the distal radius even after adjustment for age, gender and CVD/osteoporosis risk factors, supporting linkage of molecular pathways between bone disease and progression of arterial stiffness. <h3>Disclosure of Interest</h3> None declared
PWE-383 Defaecating proctography misses external rectal prolapse in 40% of cases
Authors: D James, M Penna, A Bloemendaal, S Prapasrivorakul, R Hompes, O Jones, C Cunningham, I Lindsey
Journal: Gut (2015)

<h3>Introduction</h3> External rectal prolapse (ERP) is a debilitating condition for which the only cure is surgical. There are several ways to diagnose ERP including clinical examination, defaecating proctography (DP), and examination under anaesthesia (EUA). In many cases, a diagnosis of ERP is made clinically. In our unit DP is undertaken routinely in order to aid characterisation of ERP and aiding in planning operative strategy, even when clinically evident. This affords the opportunity to evaluate DP against the gold standard of clinical assessment/EUA. The purpose of this study is to investigate the accuracy of DP in the diagnosis of ERP compared to EUA or clinical examination. Factors that may influence failure of DP in the detection of ERP are also explored. <h3>Method</h3> Data were acquired from a prospectively collected database in a tertiary referral pelvic floor service. The search was limited to those patients referred with or having a final diagnosis of ERP. Patients were included in analysis if they underwent DP and clinical examination or EUA. The primary endpoint was accuracy of DP in the diagnosis of ERP compared to a definitive diagnosis reached either by clinical examination or ultimately at EUA. Factors explored to explain any discrepancy included age and anorectal physiological parameters including maximum resting pressure (MRP, mmH<sub>2</sub>O) (Mann-Whitney U test, α=0.05). <h3>Results</h3> 113 patients had a diagnosis of ERP between July 2007 and December 2013 (median age 64y, range 18–95y, 89% female). Of these patients, 67 underwent both DP and clinical examination/EUA. 27 (40%) had a diagnosis of ERP made only on clinical examination or EUA and not detected on DP. 2 (3%) had ERP detected on DP and not on EUA. In both of these cases, grade 4 prolapse was detected at EUA and ERP on DP. Median maximum resting pressure [range] was significantly higher in those in whom DP missed compared to showed ERP (43.5 [12–122] vs. 29.5 [6–122], <i>p &lt; 0</i>.05). There was no significant difference in other ARP parameters between the two groups. There was no difference in median age [range] between the two groups (62 [25–86] vs. 55 [22–80], <i>p = 0</i>.29). <h3>Conclusion</h3> This study demonstrates the limitation of DP in the diagnosis of ERP. DP should be used with caution to diagnose the aetiology of a prolapsing lump described by a patient but not demonstrable clinically. In such patients, EUA should be considered. Patients in whom DP did not detect ERP had higher maximum resting pressure. The corollary of this may be patient difficulty reproducing ERP at DP because of better underlying sphincter function. Patients may also fail to produce their ERP at DP due to embarrassment associated with undergoing this invasive study. <h3>Disclosure of interest</h3> None Declared.
Identification of Acid-Inducing Agent and Related <italic>Mycoplasma as Mycoplasma hyorhinis</italic>
Authors: Robert H. Purcell, Norman L. Somerson, Hernon Fox, Doris C. Wong, Horace C. Turner, Robert M. Chanock
Journal: JNCI Journal of the National Cancer Institute (1966)

Identification of Acid-Inducing Agent and Related Mycoplasma as Mycoplasma hyorhinis Get access Robert H. Purcell, Robert H. Purcell Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Norman L. Somerson, Norman L. Somerson Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Hernon Fox, Hernon Fox Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Doris C. Wong, Doris C. Wong Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Horace C. Turner, Horace C. Turner Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert M. Chanock Robert M. Chanock Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases,2Bethesda, Maryland 20014 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 37, Issue 2, August 1966, Pages 251–253, https://doi.org/10.1093/jnci/37.2.251 Published: 01 August 1966 Article history Received: 20 April 1966 Published: 01 August 1966
Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis
Authors: Surendra Dasari, Md. Shahrier Amin, Paul J. Kurtin, Julie A. Vrana, Jason D. Theis, Karen L. Grogg, Mariam P. Alexander, Samih H. Nasr, Fernando C. Fervenza, Nelson Leung, Sanjeev Sethi
Journal: Kidney International (2016)
SP0183 To Publish or Perish: How to Review Manuscripts and Grant Proposals
Authors: L. Carmona
Journal: Annals of the Rheumatic Diseases (2015)

A reviewer is not someone who hates you, or who9s looking forward to having the power to "trash" your article, grant, whatever (in fact, the author is blinded many times). The reviewer is someone who will not receive any money for a week worth reviewing in her spare time. Therefore, facilitate her work: if she does not understand what you9re saying, or if you let out important information, you cannot judge that she turned your manuscript/grant down. Of note, each reviewer has a set of values and, although luck has its importance in the peer review process, it does not have as much. What will the reviewer look at? 1. Adjustment to the call/journal, whether the study has the right scope, science, researchers and budget; in this heading, the PI is a key element in the evaluation; 2. Relevance and pertinence of the research question, whether it can be identified or, on the contrary, the study is not focused, and whether it is a feasible, interesting, novel, ethical, and relevant question and well formulated; in fact a good study justification can mean to get the grant or not; 3. Internal coherence of the proposal, checking whether all parts of the method are aligned (Objectives- study subjects- design-variables-analysis); 4. Quality tips, like pilot studies, standardisation/training session, etc. 5. In some grants, the reviewer will have to check the execution capacity of the team; and 6. Whether the budget is justified. Finally, the abstract is KEY. It should have the same sections as the protocol, focus on primary objective, and be coherent. <h3>Disclosure of Interest</h3> None declared
Predictive value of the dexamethasone suppression test in mania
Authors: C D Godwin, L B Greenberg, S Shukla
Journal: American Journal of Psychiatry (1984)

Eighteen manic patients who had abnormal results on the dexamethasone suppression test at admission were retested before discharge, when they were clinically stable. Conversion to normal suppression predicted good outcome after discharge, whereas a persistently abnormal test predicted poor outcome.
Heart Failure Clinical Trials in East and Southeast Asia
Authors: Robert J. Mentz, Lothar Roessig, Barry H. Greenberg, Naoki Sato, Kaori Shinagawa, Daniel Yeo, Bernard W.K. Kwok, Eugenio B. Reyes, Henry Krum, Burkert Pieske, Stephen J. Greene, Andrew P. Ambrosy, Jacob P. Kelly, Faiez Zannad, Bertram Pitt, Carolyn S.P. Lam
Journal: JACC Heart Failure (2016)
The effect of high doses of vitamin B6 on autistic children: a double- blind crossover study
Authors: B Rimland, E Callaway, P Dreyfus
Journal: American Journal of Psychiatry (1978)

The authors used data from an earlier nonblind study to identify 16 autistic-type child outpatients who had apparently improved when given vitamin B6 (pyridoxine). In a double-blind study each child's B6 supplement was replaced during two separate experimental trial periods with either a B6 supplement or a matched placebo. Behavior was rated as deteriorating significantly during the B6 withdrawal.
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion
Authors: Takashi Kokudo, Kiyoshi Hasegawa, Yutaka Matsuyama, Tadatoshi Takayama, Namiki Izumi, Masumi Kadoya, Masatoshi Kudo, Yonson Ku, Michiie Sakamoto, Osamu Nakashima, Shuichi Kaneko, Norihiro Kokudo
Journal: Journal of Hepatology (2016)
Onset of panic disorder
Authors: C Faravelli, S Pallanti, F Biondi, S Paterniti, M A Scarpato
Journal: American Journal of Psychiatry (1992)

The situations in which the first panic attack occurred were investigated in 44 patients affected by panic disorder. Although the first panic attack was reported to be unexpected and no avoidance was present before it, 75.8% of patients (N = 22) with panic disorder with agoraphobia had their first panic attack in phobogenic situations, compared with 20% of patients (N = 3) with panic disorder without agoraphobia.
651. The CD34 Antigen Molecular Domains Implied in Potential Homing and Engraftment of Hematopoietic Progenitors
Authors: Gurudutta U. Gangenahalli, Vimal K. Singh, Soumya Pati, Yogesh K. Verma, Pallavi Gupta, Rajat Kumar, Rakesh K. Sharma, Pratibha M. Luthra
Journal: Molecular Therapy (2004)

The CD34 antigen is a 115 kD member of adhesive sialomucin family proteins present on certain hematopoietic progenitors. So far this molecule has served extensively the procedural necessity of its presence on primitive progenitors for their purification during bone-marrow transplantation (BMT). Since it initiates adhesion of progenitors to stromal layers in the marrow through stromal layer ligand, appears to be responsible for successful homing, and engraftment. Therefore, its expression and structural pattern is may be a determinant of success of BMT. It has recently been proposed that its degree of association with stromal ligandss is dependent on several cyto-plasmic and cyto-skeletal proteins, such as, Crk-I, Paxillin, c-Abl proteins interacting with its cyto-plasmic domain (Donna M. Felschow et al., 2001). We have attempted to identify the mechanistic basis of their interaction and assess the contribution to enhancement of its adhesive potential prior to evaluation of its all possible individual mutants generated by site-directed mutagenesis. We have used ab inito and silico methods to predict various functionally important residues constituting domains in CD34 that can form an active site/ligand interacting domain for Crk-L. We found that highly conserved Arg 303, Pro 307 and Pro 316 are located almost at the similar distance as they are located in other SH3 binding proteins. Although, these residues are not located in vicinity in primary structure but they can possibly interact with their counterparts in SH3 domains by attainig different conformations. Also, we have been able to validate the occurance of these predicted mechanisms in progenitors through transfection and expression of mutants containing: Arg303Ala, Pro307-Ala, Pro316-Ala, substitutions. Therefore, we propose that these substitutions mediate or necessary for CD34 to interact with Crkl, which may be essential for up-regulating the progenitors and ligand interaction, to enhance engraftment potential to CD34 progenitors usable in transplanation.
AB0236 Long Term Analysis of Remission and Relapse Rate of Bo-Dmards in RA Patients in Daily Clinical Practice
Authors: A. Ihata, K. Kobayashi, A. Osada, S. Nagaoka
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Withdrawal of boDMARDs is main concern of rheumatologists and many clinical trials were designed. However, in many reports, these observational periods were around 1 or 2 years, and long term analysis from clinical trial were few <h3>Objectives</h3> To examine the long term biologics-free remission rate and its predictive factors in daily clinical practice. <h3>Methods</h3> Retrospective observational study. 23 cases of patients who remained clinical remission (DAS28(CRP) &lt;2.6) for 3 months or more discontinued their biologics and were observed for 5 years. Clinical findings and laboratory data at the withdrawal of boDMARDs were compared between relapse group and keeping remission group. <h3>Results</h3> 15 cases of relapse were observed. The rate of remaining remission was 80.0% at 1yr, 73.9% at 2yrs and 34.8% at 5yrs. Predictive factors were DAS28(CRP) and MMP-3 at the point of discontinuation of biologics (2.1±0.2 vs 1.7±0.1, 366.0±80.5 vs 155.2 vs 33.3). Cut-off value of DAS28(CRP) was 2.0 and MMP-3 was 190.2. <h3>Conclusions</h3> Predictive factor which had already reported in several studies were valid in our long-term observational study. However, more strict remission standard was required for long-term bio-free remission. MMP-3 was also a promising predictive factor for long-term bio-free remission. <h3>Disclosure of Interest</h3> None declared
Immunologic Studies of Glycoproteins Isolated From Cell Membranes of Human Lung Carcinomas2
Authors: Thomas W. Tillack, Juan Rosai, Dorothy J. Vervynck
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Immunologic Studies of Glycoproteins Isolated From Cell Membranes of Human Lung Carcinomas Get access Thomas W. Tillack, Thomas W. Tillack Search for other works by this author on: Oxford Academic PubMed Google Scholar Juan Rosai, Juan Rosai Search for other works by this author on: Oxford Academic PubMed Google Scholar Dorothy J. Vervynck Dorothy J. Vervynck Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 52, Issue 4, April 1974, Pages 1059–1067, https://doi.org/10.1093/jnci/52.4.1059 Published: 01 April 1974 Article history Received: 07 August 1973 Accepted: 02 December 1973 Published: 01 April 1974
Influence of Sex Hormones on the Incidence and Form of Tumors Produced in Male or Female Rats by Gastric Instillation of Methylcholanthrene&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Shay, Harry, Harris, Charles, Gruenstein, Margot
Journal: JNCI Journal of the National Cancer Institute (1952)

Journal Article Influence of Sex Hormones on the Incidence and Form of Tumors Produced in Male or Female Rats by Gastric Instillation of Methylcholanthrene Get access Harry Shay, M. D., Harry Shay, M. D. Samuel S. Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar Charles Harris, M. D., Charles Harris, M. D. Samuel S. Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar Margot Gruenstein Margot Gruenstein Samuel S. Fels Research Institute, Temple University School of Medicine, Philadelphia, Pa. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 13, Issue 2, October 1952, Pages 307–331, https://doi.org/10.1093/jnci/13.2.307 Published: 01 October 1952 Article history Received: 19 March 1952 Published: 01 October 1952
AB1172 Biologic DMARD Treatment in Cyprus Based on Six Year Data from a National Hospital Covering a Population of Greek-Cypriot
Authors: S. Psarelis, E. Nikiphorou
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Biologic DMARDs have revolutionised the treatment of a number of rheumatic conditions, beyond rheumatoid arthritis (RA). Access to biologics varies across different countries. In Cyprus, the guidelines (agreed between the Cypriot Rheumatology Society and Government Pharmaceutical Services) which take into account financial constraints, recommend the cheapest anti-TNF agent as first line therapy. Between 2007 and 2013 (then after a new tender there was change in the line), the first line recommended therapy for Rheumatoid Arthritis (RA) was infliximab (3mg/kg); 2nd line etanercept and 3rd line adalimumab, whereas for Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PSA) first line was etanercept, 2nd line humira and 3rd infliximab (5mg/kg). <h3>Objectives</h3> To record the response rate and adherence to first line biologic treatments in a local population in Cyprus based on existing guidelines and recommendations. <h3>Methods</h3> This was a retrospectively evaluation of patients started on biologic treatment at the national Nicosia Hospital in Cyprus, between 2007-2013. 45 (29%) RA patients from a total 153, 20/34 (58%) AS and 21/32 (65%) PSA patients were analyzed. <h3>Results</h3> During these 6 years only 3 (15%) AS patients were changed to a second anti-TNF (2 due inefficacy, 1 due to development of inflammatory bowel disease). In the PSA group 4 (19%) patients moved to 2nd line due to inefficacy and in the RA group, 24 (54%) patients moved to 2nd line (5 due to severe infusion reactions, 3 due to infections and the rest due to inefficacy). In the case of RA if the total dose of infliximab was over 400 mg/8 weeks the protocol demanded a switch to 2nd line biologic. RA patients were 3.6 times more likely to switch to a 2nd line agent than the AS and PSA patients, mainly due to inefficacy (RR 3.6, 95% CI 1.21-10.45 p=0.02). <h3>Conclusions</h3> Etanercept was found to be generally well tolerated in AS and PsA, with patients adhering to treatment whereas in the case of RA infliximab was poorly tolerated and adhered to in the majority of patients. With the recent introduction of biosimilars and in the current financial climate, such experience should be kept in mind when developing protocols and treatment pathways, in order to optimise patient management and outcomes. <h3>Disclosure of Interest</h3> None declared
Response to Letter Regarding Article “Novel Biomarker of Oxidative Stress Is Associated With Risk of Death in Patients With Coronary Artery Disease”
Authors: Riyaz S. Patel, Nima Ghasemzadeh, Danny J. Eapen, Salman Sher, Shawn Arshad, Yi-an Ko, Emir Veledar, Habib Samady, A. Maziar Zafari, Laurence Sperling, Viola Vaccarino, Dean P. Jones, Arshed A. Quyyumi
Journal: Circulation (2016)
Missed Connections
Authors: L S Massad
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal